

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BeiGene, Ltd.
百濟神州有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 06160)

CHANGE OF DATE OF AUDIT COMMITTEE MEETING

Reference is made to the announcement issued by BeiGene, Ltd. (the “**Company**”) dated February 15, 2022 in relation to a meeting of the audit committee of the board of directors (the “**Board**”) of the Company proposed to be held on February 28, 2022 (Hong Kong Time) for the purposes of, inter alia, considering and approving the audited financial results of the Company and its subsidiaries for the year ended December 31, 2021 prepared in accordance with U.S. Generally Accepted Accounting Principles (“**U.S. GAAP**”) and the applicable rules of the U.S. Securities and Exchange Commission (the “**SEC**”) and its publication.

The Company hereby announces that a meeting of the Board will instead be held on February 25, 2022 (Hong Kong Time) to consider and approve the above.

The Company will further issue an announcement of its audited financial results for the year ended December 31, 2021 in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**HK Listing Rules**”) on or before March 31, 2022, which are expected to be the same as the annual results prepared in accordance with U.S. GAAP and the applicable rules of the SEC, except for specific additional information required by the HK Listing Rules, together with a reconciliation of the Company’s annual results from U.S. GAAP to International Financial Reporting Standards.

By order of the Board
BeiGene, Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, February 17, 2022

As of the date of this announcement, the Board of Directors of the Company comprises Mr. John V. Oyler as Chairman and Executive Director, Dr. Xiaodong Wang and Mr. Anthony C. Hooper as Non-executive Directors, and Mr. Timothy Chen, Dr. Margaret Han Dugan, Mr. Donald W. Glazer, Mr. Michael Goller, Mr. Ranjeev Krishana, Mr. Thomas Malley, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi as Independent Non-executive Directors.